You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Go to Close Top


INCS is recommended by various guidelines for allergic rhinitis

ARIA 2016

ARIA 2016 1
First-line treatment option for symptomatic patients with or without previous treatment.


AAOHNS 2015 2
Recommended for patients with a clinical diagnosis of AR where symptoms affect QoL.

BSACI 2017

BSACI 2017 3
Mainstay of anti-inflammatory intervention in AR and first-line therapy for moderate-to-severe persistent symptoms.


AAAAI / ACAAI 2017 4
Strongly recommends first-line use in patients ≥12 years of age (over OAH and INCS combination and LTRA) in SAR.

BSACI Guidelines 2017 3

Visual representation of BSACI guidelines 2017

Adapted from BSACI guidelines 2017.3

Treatment of AR in children and teenagers5

Recommended treatment pattern for children and teenagers with Allergic Rhinitis
  • Approach depends on the severity of rhinitis symptoms
  • Use a step-up or step-down therapy, depending on control obtained in response to treatment
  • OAH may be better tolerated, INAH have a more rapid onset of action
  • Reconsider diagnosis if not controlled within 1 to 2 weeks


AAAAI: American Academy of Allergy, Asthma and Immunology; AAOHNS: American Academy of Otolaryngology - Head and Neck Surgery; ACAAI: American College of Allergy, Asthma, and Immunology; AH: Antihistamine; AR: Allergic rhinitis; ARIA: Allergic Rhinitis and its Impact on Asthma; BSACI: British Society for Allergy and Clinical Immunology; INAH: Intranasal antihistamine; INCS: Intranasal corticosteroids; LTRA: Leukotriene receptor antagonist; OAH: Oral antihistamine; QoL: Quality of life; Rx: Medical prescription; SAR: Seasonal allergic rhinitis.


  1. Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958.
  2. Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Head Neck Surg. 2015:152(18) S1-S43.
  3. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2017;47:856-889.
  4. Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017;167(12):876-881.
  5. Santos A, Borrego LM, Rotiroti G, et al. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015;5:2.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Avamys is a registered trademark of the GlaxoSmithKline group of companies